Financial reports and presentations

12 August 2020

VACCIBODY AND NEKTAR THERAPEUTICS DOSES FIRST PATIENT IN PHASE 1/2A STUDY ARM EVALUATING VB10.NEO IN COMBINATION WITH BEMPEGALDESLEUKIN

First patient dosed in VB N-01 study arm with VB10.NEO plus Bempegaldesleukin (NKTR-214)